Our results strongly suggest that aberrant BMP-2 methylation and the resultant loss of BMP-2 expression may be useful as a biomarker for designing improved diagnostic and therapeutic strategies for advanced RCC. The gene discussed is BMP2; the disease is renal cell carcinoma.